{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T22:09:56Z","timestamp":1778278196942,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.intimp.2023.110617","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T16:36:50Z","timestamp":1689784610000},"page":"110617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy"],"prefix":"10.1016","volume":"122","author":[{"given":"Zhou-rui","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian-wei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-zhong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-tao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-hong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-liang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5252-7096","authenticated-orcid":false,"given":"Xiang-ming","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2023.110617_b0005","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1615\/CritRevEukaryotGeneExpr.2020028454","article-title":"Malignant melanoma: skin cancer-diagnosis, prevention, and treatment","volume":"30","author":"Ahmed","year":"2020","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"10.1016\/j.intimp.2023.110617_b0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-3-319-22539-5_4","article-title":"Melanoma: clinical presentations","volume":"167","author":"Kibbi","year":"2016","journal-title":"Cancer Treat. Res."},{"key":"10.1016\/j.intimp.2023.110617_b0015","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920925219","article-title":"Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations","volume":"12","author":"Giunta","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2023.110617_b0020","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"7494","key":"10.1016\/j.intimp.2023.110617_b0025","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.intimp.2023.110617_b0030","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049229","article-title":"RAS pathway regulation in melanoma","volume":"15","author":"Al Mahi","year":"2022","journal-title":"Dis. Model. Mech."},{"issue":"15","key":"10.1016\/j.intimp.2023.110617_b0035","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/s41388-022-02244-7","article-title":"Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147\/VEGFR-2 interaction","volume":"41","author":"Landras","year":"2022","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.intimp.2023.110617_b0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1158\/2767-9764.CRC-21-0033","article-title":"HSP70 inhibition blocks adaptive resistance and synergizes with MEK inhibition for the treatment of NRAS-mutant melanoma","volume":"1","author":"Parris","year":"2021","journal-title":"Cancer Res. Commun."},{"issue":"11","key":"10.1016\/j.intimp.2023.110617_b0045","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/0008-5472.CAN-19-0040","article-title":"HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy","volume":"79","author":"Emmons","year":"2019","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2023.110617_b0050","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1158\/0008-5472.CAN-17-1318","article-title":"miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma","volume":"78","author":"Diaz-Martinez","year":"2018","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2023.110617_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129365","article-title":"USP18 sensitivity of peptide transporters PEPT1 and PEPT2","volume":"10","author":"Warsi","year":"2015","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.intimp.2023.110617_b0060","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1158\/1541-7786.MCR-16-0369","article-title":"Deubiquitinase USP18 loss mislocalizes and destabilizes KRAS in lung cancer","volume":"15","author":"Mustachio","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.intimp.2023.110617_b0065","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-020-01442-1","article-title":"USP18 directly regulates Snail1 protein through ubiquitination pathway in colorectal cancer","volume":"20","author":"Huang","year":"2020","journal-title":"Cancer Cell Int."},{"issue":"12","key":"10.1016\/j.intimp.2023.110617_b0070","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.4161\/cbt.26525","article-title":"The DeISGylase USP18 limits TRAIL-induced apoptosis through the regulation of TRAIL levels: cellular levels of TRAIL influences responsiveness to TRAIL-induced apoptosis","volume":"14","author":"Manini","year":"2013","journal-title":"Cancer Biol. Ther."},{"issue":"7668","key":"10.1016\/j.intimp.2023.110617_b0075","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature23449","article-title":"cGAS surveillance of micronuclei links genome instability to innate immunity","volume":"548","author":"Mackenzie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2023.110617_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00615","article-title":"Research advances in how the cGAS-STING pathway controls the cellular inflammatory response","volume":"11","author":"Wan","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110617_b0085","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.molcel.2016.08.025","article-title":"TRIM14 inhibits cGAS degradation mediated by selective autophagy receptor p62 to promote innate immune responses","volume":"64","author":"Chen","year":"2016","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.intimp.2023.110617_b0090","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11523-018-0565-2","article-title":"The role of autophagy in the resistance to BRAF inhibition in BRAF-mutated melanoma","volume":"13","author":"Liu","year":"2018","journal-title":"Target. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110617_b0095","article-title":"Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance","volume":"10","author":"Li","year":"2019","journal-title":"Nat. Commun."},{"issue":"30","key":"10.1016\/j.intimp.2023.110617_b0100","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.18632\/oncotarget.27673","article-title":"cGAS-STING pathway in oncogenesis and cancer therapeutics","volume":"11","author":"Hoong","year":"2020","journal-title":"Oncotarget"},{"issue":"551","key":"10.1016\/j.intimp.2023.110617_b0105","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5683","article-title":"PRMT5 control of cGAS\/STING and NLRC5 pathways define melanoma response to anti-tumor immunity","volume":"12","author":"Kim","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.intimp.2023.110617_b0110","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.4049\/jimmunol.1900514","article-title":"Cutting edge: USP27X deubiquitinates and stabilizes the DNA sensor cGAS to regulate cytosolic DNA-mediated signaling","volume":"203","author":"Guo","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.110617_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2022.06.001","article-title":"Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma","volume":"26","author":"Kim","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"issue":"1","key":"10.1016\/j.intimp.2023.110617_b0120","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1674-8301(10)60009-7","article-title":"Construction and identification of recombinant lentiviral vector containing HIV-1 Tat gene and its expression in 293T cells","volume":"24","author":"Wei","year":"2010","journal-title":"J. Biomed. Res."},{"issue":"3","key":"10.1016\/j.intimp.2023.110617_b0125","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.3892\/mmr.2017.6974","article-title":"Selection of an optimal promoter for gene transfer in normal B cells","volume":"16","author":"Winiarska","year":"2017","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2023.110617_b0130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jconrel.2005.02.006","article-title":"Target-specific gene silencing by siRNA plasmid DNA complexed with folate-modified poly(ethylenimine)","volume":"104","author":"Hwa Kim","year":"2005","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.intimp.2023.110617_b0135","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/sj.gt.3300835","article-title":"Adeno-retroviral chimeric viruses as in vivo transducing agents","volume":"6","author":"Caplen","year":"1999","journal-title":"Gene Ther."},{"issue":"3","key":"10.1016\/j.intimp.2023.110617_b0140","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1039\/D0BM00870B","article-title":"The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma","volume":"9","author":"Li","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.intimp.2023.110617_b0145","article-title":"Anti-tumor activity of cGAMP via stimulation of cGAS-cGAMP-STING-IRF3 mediated innate immune response","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"issue":"20","key":"10.1016\/j.intimp.2023.110617_b0150","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"46","key":"10.1016\/j.intimp.2023.110617_b0155","doi-asserted-by":"crossref","first-page":"12196","DOI":"10.1073\/pnas.1708744114","article-title":"DsbA-L prevents obesity-induced inflammation and insulin resistance by suppressing the mtDNA release-activated cGAS-cGAMP-STING pathway","volume":"114","author":"Bai","year":"2017","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2023.110617_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105514","article-title":"Intrinsic strategies for the evasion of cGAS-STING signaling-mediated immune surveillance in human cancer: How therapy can overcome them","volume":"166","author":"Zou","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.intimp.2023.110617_b0165","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/1535-7163.MCT-17-0919","article-title":"Targeting the proteasome-associated deubiquitinating enzyme USP14 impairs melanoma cell survival and overcomes resistance to MAPK-targeting therapies","volume":"17","author":"Didier","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.intimp.2023.110617_b0170","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2021.12655","article-title":"USP22 promotes melanoma and BRAF inhibitor resistance via YAP stabilization","volume":"21","author":"Wei","year":"2021","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.intimp.2023.110617_b0175","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1158\/1541-7786.MCR-20-0579","article-title":"The ubiquitin-specific peptidase USP18 promotes lipolysis, fatty acid oxidation, and lung cancer growth","volume":"19","author":"Liu","year":"2021","journal-title":"Mol. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2023.110617_b0180","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1158\/0008-5472.CAN-17-1752","article-title":"Evidence for the ISG15-specific deubiquitinase USP18 as an antineoplastic target","volume":"78","author":"Mustachio","year":"2018","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2023.110617_b0185","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1210\/jc.2016-1999","article-title":"Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib","volume":"102","author":"Wang","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.intimp.2023.110617_b0190","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.19671","article-title":"Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors","volume":"6","author":"Mulcahy Levy","year":"2017","journal-title":"Elife"},{"issue":"12","key":"10.1016\/j.intimp.2023.110617_b0195","doi-asserted-by":"crossref","first-page":"237","DOI":"10.21037\/atm.2016.06.07","article-title":"Resistant mechanisms to BRAF inhibitors in melanoma","volume":"4","author":"Manzano","year":"2016","journal-title":"Ann. Transl. Med."},{"issue":"8","key":"10.1016\/j.intimp.2023.110617_b0200","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-022-05136-6","article-title":"USP7 regulates the ERK1\/2 signaling pathway through deubiquitinating Raf-1 in lung adenocarcinoma","volume":"13","author":"Park","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2023.110617_b0205","doi-asserted-by":"crossref","unstructured":"A. Saei, M. Palafox, T. Benoukraf, N. Kumari, P.W. Jaynes, P.V. Iyengar, E. Munoz-Couselo, P. Nuciforo, J. Cortes, C. Notzel, N.B. Kumarakulasinghe, J.L.C. Richard, Z.F. Bin Adam Isa, B. Pang, M. Guzman, Z. Siqin, H. Yang, W.L. Tam, V. Serra, P.J.A. Eichhorn, Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies, J. Exp. Med. 215 (7) (2018) 1913\u20131928.","DOI":"10.1084\/jem.20171960"},{"issue":"14","key":"10.1016\/j.intimp.2023.110617_b0210","doi-asserted-by":"crossref","first-page":"5559","DOI":"10.18632\/oncotarget.2140","article-title":"Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway","volume":"5","author":"Potu","year":"2014","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.intimp.2023.110617_b0215","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1631\/jzus.B2000309","article-title":"Role of deubiquitinating enzymes in DNA double-strand break repair","volume":"22","author":"Li","year":"2021","journal-title":"J. Zhejiang Univ. Sci. B"},{"issue":"19","key":"10.1016\/j.intimp.2023.110617_b0220","doi-asserted-by":"crossref","first-page":"19273","DOI":"10.18632\/aging.103760","article-title":"Deubiquitinase USP18 promotes the progression of pancreatic cancer via enhancing the Notch1-c-Myc axis","volume":"12","author":"Feng","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"10.1016\/j.intimp.2023.110617_b0225","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/cdd.2017.165","article-title":"N6-isopentenyl adenosine dual targeting of AMPK and Rab7 prenylation inhibits melanoma growth through the impairment of autophagic flux","volume":"25","author":"Ranieri","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.intimp.2023.110617_b0230","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1476-4598-13-132","article-title":"USP18 is crucial for IFN-gamma-mediated inhibition of B16 melanoma tumorigenesis and anti-tumor immunity","volume":"13","author":"Hong","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2023.110617_b0235","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bbrc.2022.02.048","article-title":"USP18 reduces paclitaxel sensitivity of triple-negative breast cancer via autophagy","volume":"599","author":"Ge","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.intimp.2023.110617_b0240","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180250","article-title":"USP18 - a multifunctional component in the interferon response","volume":"38","author":"Basters","year":"2018","journal-title":"Biosci. Rep."},{"issue":"12","key":"10.1016\/j.intimp.2023.110617_b0245","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/cr.2016.125","article-title":"USP18 recruits USP20 to promote innate antiviral response through deubiquitinating STING\/MITA","volume":"26","author":"Zhang","year":"2016","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.intimp.2023.110617_b0250","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-021-02278-9","article-title":"Genotoxic stress in constitutive trisomies induces autophagy and the innate immune response via the cGAS-STING pathway","volume":"4","author":"Krivega","year":"2021","journal-title":"Commun Biol"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923009426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923009426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:25:29Z","timestamp":1736432729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923009426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":50,"alternative-id":["S1567576923009426"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110617","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110617","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110617"}}